The Series A financing was led by Par Equity to support international expansion and product development.
"Securing this investment allows us to scale our impact across healthcare and life sciences, with a focus on easing the burden of paediatric clinical trials. While legislation like RACE, SPCs, and the ODA has increased study numbers, specialist paediatric knowledge is still lacking in the industry. This has led to lower recruitment, adherence and trial completion rates compared to adult research. Little Journey is uniquely positioned to fill this expertise gap and tackle these challenges to advance global paediatric medicine. With the backing of Par Equity, Mercia Ventures, Octopus Ventures, and our wider investor network, we’re redefining how paediatric clinical trials are run and putting families at the heart of them."
The pre-seed round was led by YZR Capital to support clinical trials and platform development for eating disorder care.
"The widening gap between the need for care and available resources, along with the lack of personalised treatment options, urgently requires a radical rethink of how eating disorder care is provided. Our goal is to revolutionise care pathways, providing tools that empower clinicians and deliver meaningful results. We aim to keep people out of hospital and enable better long-term recovery while saving costs for the healthcare system. Univa’s platform will augment the overwhelmed clinical workforce by providing evidence-based tools to reach more patients and families, enabling earlier intervention, improved monitoring, and faster recovery."
The funding round was led by Octopus Ventures with backing from JamJar and Forward Partners.
"This latest injection of funding – from experienced investors with a proven track record of backing successful fertility and femtech businesses – will enable us to get our pioneering treatment in the hands of the people who need it most. We can’t wait for people to try it."
The London based healthtech startup secured backing from investors including Entrepreneur First and Form Ventures to expand its platform into clinical settings.
"Our technology is revolutionary. By combining cutting edge neuroscience and ethical, explainable AI, we have built a tool that can help people get an accurate diagnosis and effective treatment plan in place faster than ever before. It’s all about arming clinicians with the very best tools so that they can do the very best by their patients. We’re so grateful for the support our investors have shown us so far; and we look forward to this next stage of our journey as we look to optimise and expand our technology and get it in the hands of the people who need it most."
The seed round was led by Notion Capital and Triple Point Ventures to support team growth and clinical service expansion.
"Although there is 8x more spent on assisted reproductive technology (ART, including IVF, IUI, ICSI, etc) in Europe over the US, there are three unicorn companies in the US and none in Europe. It’s clear that there is a massive opportunity for a team with commitment to better outcomes to make a significant impact. We believe we have found this in Fertifa and are excited to see what can be achieved."
